Oppenheimer Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Viridian Therapeutics (NASDAQ:VRDN) had its target price lifted by Oppenheimer from $28.00 to $32.00 in a report released on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

VRDN has been the topic of a number of other research reports. Needham & Company LLC dropped their price objective on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Wednesday. The Goldman Sachs Group dropped their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. JMP Securities lowered their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 7th. Finally, Royal Bank Of Canada cut their target price on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Viridian Therapeutics Trading Down 3.9%

Shares of NASDAQ:VRDN opened at $16.53 on Thursday. The firm has a fifty day moving average of $15.89 and a two-hundred day moving average of $15.23. The company has a quick ratio of 19.49, a current ratio of 19.49 and a debt-to-equity ratio of 0.05. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $27.20. The firm has a market capitalization of $1.35 billion, a P/E ratio of -4.32 and a beta of 0.42.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 72.85% and a negative net margin of 112,806.88%. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.05 million. During the same quarter last year, the firm earned ($0.81) earnings per share. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, equities analysts expect that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Viridian Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Amalgamated Bank lifted its position in shares of Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after purchasing an additional 840 shares during the last quarter. Nuveen Asset Management LLC increased its position in Viridian Therapeutics by 198.2% in the 4th quarter. Nuveen Asset Management LLC now owns 681,012 shares of the company’s stock worth $13,055,000 after buying an additional 452,627 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Viridian Therapeutics by 17.0% during the first quarter. Principal Financial Group Inc. now owns 208,836 shares of the company’s stock worth $2,815,000 after buying an additional 30,392 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Viridian Therapeutics by 4.0% in the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company’s stock valued at $88,087,000 after acquiring an additional 174,952 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Viridian Therapeutics by 4.6% in the first quarter. Rhumbline Advisers now owns 104,559 shares of the company’s stock valued at $1,409,000 after acquiring an additional 4,621 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.